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ABSTRACT 
 
Gluconeogenesis is a biochemical process through which the organs or cells can 
synthesize glucose from non-carbohydrate carbon substrates and is important for blood 
glucose homeostasis. Multiple enzymes participate in this process. Among these 
enzymes, PEPCK1 and G6PC are the two most important rate-limiting enzymes. Given 
the key roles of PEPCK1 and G6PC in gluconeogenesis, expression of these two genes is 
regulated by multiple transcription factors. FoxO1 and FoxO3a are the two members of 
FoxO family that is involved in the regulation of PEPCK1 and G6PC expressions. The 
subcellular localization and transcription activity of FoxO1/3a are tightly regulated by 
their phosphorylation status. Akt is an important regulator of FoxO1/3a through 
phosphorylating FoxO1/3a at the key serine/threonine residues. MAPK phosphatase 3 
can promote gluconeogenesis by dephosphorylating FoxO1 in mouse liver and PP2A 
was reported to be a phosphatase which can dephosphorylate FoxO1/3a in vitro and in 
cells. The nuclear localized phosphatase, which can regulate FoxO1/3a function on 
gluconeogenesis, is not found yet. Based on microarray database, we targeted a small C-
terminal phosphatase as a potential FoxOs phosphatase. The role of this phosphatase was 
verified by using in vitro dephosphorylating and binding assay, cell based biochemistry 
and immunofluorescence assay, and knock out mouse model. In our study, we identified 
SMP5 as a new FoxO1/3a phosphatase. We showed that SMP5 co-localized and 
interacted with FoxO1/3a in the nucleus. SMP5 dephosphorylates FoxO1/3a in 
ser256/253, respectively. We also found that SMP5 facilitates FoxO1/3a nuclear 
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localization and enhances their transcriptional activities. SMP5 KO mice have severe 
hypoglycemia and died within 24 hours after birth. FoxO1 and FoxO3a phosphorylation 
are increased. Thus, our findings indicate SMP5 is a FoxO1/3a phosphatase which 
controls their phosphorylation and nuclear localization, and in turn regulates their 
transcription activities on PEPCK1 and G6PC expression. Our study presents novel 
insights into the regulation of FoxO1/3a transcription activities by a new phosphatase 
during glucose homeostasis. 
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NOMENCLATURE 
 
cAMP             Cyclic adenosine monophosphate 
CREB             cAMP response element-binding protein 
CRTC2           CREB regulated transcription co-activator 2 
CTDSP           Small C-terminal domain phosphatase 
C/EBP            CCAAT-enhancer-binding protein 
DAF-16          C.elegans forkhead box O homologue 
DMEM            Dulbecco's modified eagle medium 
DUSP              Dual-specificity phosphatase 
EMEM            Eagle's minimum essential medium 
FoxO               Forkhead box O family transcription factor 
G6PC              Glucose-6-phosphatase 
GST                Glutathione S-transferase 
Gys1               Glycogen synthase 1 
Gys2               Glycogen synthase 2 
HNF4α            Hepatocyte nuclear factor 4, alpha 
Het                  Heterozygous 
Homo              Homozygous 
MEF                Mouse embryonic fibroblast 
MKP3             MAP kinase phosphatase 3 
NEAA             Non-essential amino acids 
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PEPCK1          Phosphoenolpyruvate carboxykinase 
PI3K                Phosphoinositide 3-kinase 
PKA                 Protein kinase A 
PKB                 Protein kinase B 
PP2A                Protein phosphatase 2 
PSA                  Periodic acid–Schiff staining 
PTP                  Protein tyrosine phosphatase 
Pygl                  Glycogen phosphorylase liver form 
qPCR               quantitative PCR 
SDS-PAGE     Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SMP5              CTDSPL2 
SMP5DN        CTDSPL2 (Asp to Asn substitution at a.a. 295)               
S/TP               Serine/Threonine phosphatase 
WCL              Whole cell lysate 
VSD               Ventricle septum defect 
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CHAPTER I  
GENERAL INTRODUCTION 
GLUCOSE HOMEOSTASIS 
Glucose is the most important and primary energy source for the organs in 
human. To support the physiological function of different organs, the plasma glucose 
concentration should be maintained within a relatively narrow range. Neither High blood 
glucose (hyperglycemia) nor low blood glucose (hypoglycemia) is acceptable for body 
health. Long term hyperglycemia can cause diseases in different organs including: 
cardiovascular, kidney, nerve system, and eye. Given the limitation in the alternate fuels 
for the brain and the ability of glucose to be transported across the blood brain barrier, it 
is undoubted that blood glucose is the main energy resource for brain and hypoglycemia 
will cause the brain damage due to the energy supply cut off. Glucose is also the 
irreplaceable energy source for the mammalian erythrocytes and avian retina (Krebs 
1972). The blood glucose level is sophisticate regulated during the feeding and fasting 
circle in mammalian. The transient increasing of blood glucose after feeding can trigger 
the pancreas beta cells to release insulin which in turn stimulates the glucose up take by 
skeletal muscle and liver. In the fasting stage, multiple hormones including glucagon, 
catecholamine, cortisol and growth hormone will be released into circulation and 
stimulate the glucose releasing by liver and kidney. 
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HEPATIC GLUCOSE PRODUCTION 
As a major organ that plays important role in blood glucose homeostasis, liver 
supplies glucose to maintain the constant blood glucose level during fasting period. The 
glucose released from liver comes from two resources. One is glycogenolysis, through 
which the liver glycogen is degraded into glucose. The other one is gluconeogenesis, 
with this the hepatocyte can de novo synthesize glucose with non-carbohydrate carbon 
substrates (pyruvate, lactate, glycerol, glucogenic amino acids, and odd-chain fatty 
acids). Gluconeogenesis plays important role for blood glucose homeostasis at prolong 
starvation condition at which the liver glycogen is depleted by glycogenolysis.  
PEPCK1 AND G6PC 
There are multiple enzymes participate gluconeogenesis. Pyruvate carboxylase 
catalyzes the transform from pyruvate to oxaloacetate which can be transported from 
mitochondrial to cytoplasm.  The oxaloacetate is transformed into phosphoenolpyruvate 
by PEPCK1. Then the phosphoenolpyruvate is transformed to glucose-6-phosphate step 
by step with catalysis of enolase, phosphoglycerate mutase, phosphoglycerate kinase, 
glyceraldehyde-3-phosphate dehydrogenase, aldolase, fructose-1, 6 -bisphosphatse and 
phosphoglucose isomerase. The final step is catalyzed by glucose-6-phosphatase which 
transforms glucose-6-phosphate into glucose (Figure 1.1). PEPCK1 and G6PC are two 
rate-limiting enzymes among these enzymes for gluconeogenesis. 
PEPCK1, also named as PECPK-C, is the cytosolic isoform of PEPCK and the 
other one is mitochondrial PEPCK which is known as PEPCK-M. PEPCK-M is the first 
PEPCK isoform which is found in chicken liver at 1954 (Utter and Kurahashi 1954). 
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PEPCK-C was found after the discovery of PEPCK-M. (Nordlie and Lardy 1963) The 
role of PEPCK1 in metabolism is extensively studied in the half century after it was 
disclosed (Chakravarty, Cassuto et al. 2005). Given the important role of PEPCK1 in 
glucose metabolism, it is considered to be a bio-marker for hepatic gluconeogenesis and 
the mRNA level of PEPCK1 is possible to be used as an indicator for the evaluation of 
type 2 diabetes. In adult mouse, PEPCK1 is mainly expressed in liver, kidney and 
adipose tissue, and it is also detected in other tissues such as skeletal muscle, brain and 
colon. In mouse embryo, PEPCK1 can be found in nervous system (Zimmer and 
Magnuson 1990).  
G6PC is an endoplasmic reticulum membrane bounded phosphatase which can 
remove the phosphate group from glucose-6-phosphate to form glucose. The first 
evidence of the existing of this enzyme was reported by de Duve and co-workers at 
1949, they found there is an ER cell fractionation associated phosphatase specifically 
acts on Glucose-6-phosphate (De Duve 1949; Hers, Berthet et al. 1951). The G6PC gene 
was cloned at 1993 (Lei, Shelly et al. 1993; Shelly, Lei et al. 1993) and the function of 
G6PC was also intensively studied after it was discovered. As an important enzyme for 
gluconeogenesis, G6PC mainly expresses in liver and kidney cortex(Hers and De Duve 
1950). The intestine is also an organ in which G6PC expresses particularly at starvation 
and diabetes conditions (Rajas, Bruni et al. 1999). Furthermore, it was reported that 
G6PC expresses in pancreas β-cells, muscle, astrocytes and placenta (Forsyth, Bartlett et 
al. 1993; Khan, Hong-Lie et al. 1995; Gamberucci, Marcolongo et al. 1996; Matsubara, 
Takizawa et al. 1999)  
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Figure 1.1 Flow chart of gluconeogenesis. The flow chart presents the biochemistry 
process of gluconeogenesis and the involved enzymes.  
 
 
 
 
e
e 
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TRANSCRIPTIONAL REGULATION OF PEPCK1 AND G6PC IN LIVER 
Consistent with the role in metabolism, the expression of PEPCK1 is tightly 
regulated by multiple metabolism related hormones such as insulin, glucagon, and 
glucocorticoid. Briefly, glucagon and glucocorticoid can stimulate PEPCK1 expression 
vice versa insulin can inhibit PEPCK1 expression in liver. Glucagon receptor is a G-
protein coupled receptor which can activate adenylate cyclase to increase endogenous 
cAMP after binding with glucagon(Brubaker and Drucker 2002). As a nuclear receptor, 
the cytosol localized glucocorticoid receptor can re-localize into nucleus and activate 
down-stream genes expression including PEPCK1 and G6PC after binding with 
glucocorticoid (Lu, Wardell et al. 2006).  There are different transcription factors and 
co-factors which can response to the different stimulation of the hormones and regulate 
PEPCK1 gene transcription. Promoter region analysis reveals multiple binding sites on 
the promoter for different transcription factors including glucocorticoid receptor, CREB, 
HNF4α, C/EBPα/β, and FoxO proteins(Chakravarty, Cassuto et al. 2005). After 
phosphorylated by the cAMP activated PKA, CREB binds to the cAMP-responsive 
element (CRE) on the PEPCK1 promoter and up-regulate PEPCK1 expression (Mayr 
and Montminy 2001).  C/EBP can also bind to the CRE site and modulate PEPCK1 
gene’s transcription (Park, Roesler et al. 1990; Park, Gurney et al. 1993). The function of 
HNF4α on PEPCK1 expression has been proved by using HNF4α liver-specific 
knockout mice which has the PEPCK1 mRNA level decreasing in liver (Rhee, Inoue et 
al. 2003). FoxO1 can interact with the insulin responsive element (IRE) on the PEPCK1 
promoter and ectopic expressing FoxO1 in db/db mouse liver can up-regulate PEPCK1 
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mRNA level (Durham, Suwanichkul et al. 1999; Altomonte, Richter et al. 2003). 
Besides the transcription factors, there are transcription co-factors also participate in 
PEPCK1 expression regulation. CREB regulated transcription co-activator 2 (CRTC2) 
can bind with phospho-CREB and enhance its transcription activity on PEPCK1 (Koo, 
Flechner et al. 2005). Peroxisome proliferator activated receptor coactivator-1 (PGC-1) 
can interact with HNF4α and FoxO1 to modulate PEPCK1 transcription (Rhee, Inoue et 
al. 2003). The transcriptional regulation of G6PC is quiet similar to the regulation of 
PEPCK1 given they highly related roles in the liver gluconeogenesis. CREB and its co-
activator CRTC2 were found to be a positive regulator for G6PC under starvation status 
(Mayr and Montminy 2001; Koo, Flechner et al. 2005). Conditional knockout C/EBPα 
in mouse liver can dramatically decrease G6PC mRNA levels suggesting the role of 
C/EBPα in G6PC expression (Yang, Croniger et al. 2005). Liver G6PC expression 
decreasing was also found in HNF4α knockout mice (Rhee, Inoue et al. 2003). There are 
multiple IRE sites on the G6PC promoter on which FoxO proteins can bind and 
overexpression of FoxO1 can enhance G6PC expression (Schmoll, Walker et al. 2000; 
Vander Kooi, Streeper et al. 2003). CRTC2 and PGC-1α also were found to be the 
positive regulator for G6PC (Rhee, Inoue et al. 2003; Koo, Flechner et al. 2005). 
FOXO PROTEIN FAMILY 
Forkhead box class O (FoxO) proteins are belonging to a subgroup of the Fox 
family of transcription factors which have the conserved winged helix DNA-binding 
domain (the forkhead box). There are four FoxO genes found in mammals, including 
FoxO1, 3, 4 and 6. FoxO1 (FKHR) is the first member of FoxO genes and it was initially 
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identified in human rhabdomyosarcoma that has chromosomal rearrangements (Galili, 
Davis et al. 1993; Davis, D'Cruz et al. 1994). Soon after FoxO genes were found in 
human, the homologue of human FoxO was found in C.elegans as DAF-16 (Ogg, 
Paradis et al. 1997). It is reported that lost function mutation of daf-16 can rescue the 
phenotype of daf-2 (homologue of ISR) or age-1/daf23 (homologue of PI3K) mutation 
which suggests it play roles in insulin/PI3K/Akt signal pathway (Ogg, Paradis et al. 
1997). It was shown in further studies that FoxO proteins play important roles in 
proliferation, metabolism, life span and stress resistance (Barthel, Schmoll et al. 2005; 
Greer and Brunet 2005; Kousteni 2012). Normally, FoxO proteins localize in cell 
nucleus in active state. In response to growth factors and insulin, FoxO proteins can be 
phosphorylated by Akt at three consensus Akt phosphorylation sites. Phosphorylation of 
FoxO proteins triggers inactivating these proteins and exporting them from nucleus (Van 
Der Heide, Hoekman et al. 2004).  
REGULATION OF FOXO PROTEINS 
As the transcription factors that active or inhibit different downstream genes 
which are related to different biological processes, FoxO proteins need to be tightly 
regulated to meet different conditions including cell proliferation, apoptosis, stress 
response and metabolism. FoxO are mediated in transcription/post-transcription level as 
well as in post-translational level. The expression of FoxO genes can be repressed by 
growth factors including: FGF, PDGF and IGF-1 in human fibroblast cells (Valenti, 
Rametta et al. 2008; Essaghir, Dif et al. 2009).  FoxO3a has been reported to be directly 
downstream target of p53 (Renault, Thekkat et al. 2011). miR-155 has been identified as 
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a repressor for FoxO3a in conventional T cells and HOZOT cells (Yamamoto, Kondo et 
al. 2011). There are Ser/Thr sites distributing on FoxO proteins which can be 
phosphorylated by multiple Ser/Thr kinases (Figure 1.2 and Figure 1.3). Akt/PKB was 
reported to repress FoxO activity through phosphorylating FoxO and promote their 
nucleus exclusion (Biggs, Meisenhelder et al. 1999; Brunet, Bonni et al. 1999; Kops, de 
Ruiter et al. 1999).Phosphorylating by GSK is required for casein kinase1 mediated 
FoxO nuclear export (Rena, Woods et al. 2002). MST/Hippo can phosphorylate to 
disrupt their interaction with 14-3-3 and in turn facilitate nuclear localization (Lehtinen, 
Yuan et al. 2006; Yuan, Lehtinen et al. 2009). Cdk1 phosphorylates FoxO1 in neurons to 
active apoptosis (Kim and Bonni 2008; Yuan, Becker et al. 2008). AMPK was reported 
to phosphorylate FoxO3 and enhance its transcription activity (El Gazzar, Yoza et al. 
2007). FoxO3a can be phosphorylated by Erk and its activity is repressed by the 
phosphorylation (Hu, Lee et al. 2004; Yang, Zong et al. 2008). Phosphatases PP2A and 
MKP3 dephosphorylate FoxO1 and facilitate its nuclear localization (Yan, Lavin et al. 
2008; Wu, Jiao et al. 2010). Acetylation has also been found to regulate FoxO protein 
transcription activity. After acetylated by CBP/P300, the DNA binding capacity of 
FoxO3a is diminished and cytosol distribution is increased. The member of HDAC 
family, Sirt1 was shown to interact and deacetylate FoxO3 to affect its transcription 
activity (Brunet, Sweeney et al. 2004; Kobayashi, Furukawa-Hibi et al. 2005). 
Methylation also regulates FoxO activity, protein arginine methyltransferase PRMT1 
can methylate FoxO1 and block Akt mediated phosphorylation (Yamagata, Daitoku et 
al. 2008). Set9 is reported to methylate FoxO3a and repress its activity (Xie, Hao et al. 
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2012). Finally, glycosylation was shown to be a factor which can mediate FoxO activity. 
With O-glycosylation, the transcription activity of FoxO1 is up-regulated and the 
gluconeogenesis related downstream genes expression is increased (Housley, Rodgers et 
al. 2008; Kuo, Zilberfarb et al. 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Phosphorylation sites of human FoxO1 protein. FoxO1 is directly 
phosphorylated by diverse protein kinase at multiple Serine/Threonine (S/T) sites. (1) 
Threonine 24 and Serine 256/319 sites are phosphorylated by Akt, SGK and PKA. (2) 
Serine 212 site is phosphorylated by MST. (3) Serine 249 site is phosphorylated by 
CDK1/2. (4) Serine 322/325 sites are phosphorylated by CK1. (DBD: DNA Binding 
Domain, NLS: Nucleus Localization Sequence, NES: Nucleus Export Sequence, TAD: 
Transcription Activation Domain) 
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Figure 1.3 Phosphorylation sites of human FoxO3a protein. FoxO3a is directly 
phosphorylated by diverse protein kinase at multiple Serine/Threonine (S/T) sites. (1) 
Threonine 32 and Serine 253/315 sites are phosphorylated by Akt, SGK and PKA. (2) 
Serine 207 site is phosphorylated by MST. (3) Serine 294/344 sites are phosphorylated 
by Erk. (DBD: DNA Binding Domain, NLS: Nucleus Localization Sequence, NES: 
Nucleus Export Sequence, TAD: Transcription Activation Domain) 
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FOXO PROTEINS AND AKT 
DAF-16, the C. elegans homologues of FoxO proteins is the first identified 
downstream transcriptional factor of insulin-PI3K-Akt signaling pathway (Lin, Dorman 
et al. 1997; Ogg, Paradis et al. 1997).  As a direct upstream regulation kinase, Akt plays 
important role in regulating FoxO proteins transcriptional activity. Mutiple conserved 
Akt phosphorylation sites have been found from C.elegans to mammals. There are 
T54/24/32, S240/256/253, and S314/319/315 in DAF16, FoxO1 and FoxO3 respecively 
which can be phosphoralated by Akt  and increasing of phosphorylation in these sites 
enhances the proteins nucleus export and diminishs FoxO transcriptional activity 
(Paradis and Ruvkun 1998; Brunet, Bonni et al. 1999; Rena, Guo et al. 1999). FoxO4 is 
also regulated by Akt with similar mechanism (Kops, de Ruiter et al. 1999). Among 
these sites, S256/253 site of  is the most important and primary site for Akt regulation; 
Phosphoraltion of the other two sites is depend on the S256/253 site 
phosphorylation(Nakae, Park et al. 1999).   
Akt (protein kinase B, PKB) is a serine/threonine specific protein kinase. There 
are three members of this family including Akt1, Akt2 and Akt3. Altough they share 
high similar amino acids seuqence, their functions are different. The Akt1 knockout 
mice have growth retardation phenotype, decreased life span under stress and increased 
spontaneous apoptosis in testes (Chen, Xu et al. 2001). Akt2 knockout mouse shows 
insulin resistance and dramatically age dependent adipose tissue decrease (Garofalo, 
Orena et al. 2003). The knockout mouse data suggests that Akt1 participates the singal 
pathways related to cell survive with the apoptosis inhibiting function and Akt2 mainly 
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plays a role in metabolic regulation. Unlike the ubiqutiouly expression pattern of Akt1/2, 
Akt3 is sepcificlly expressed in neuronal tissue and Akt3 knock out mouse has small 
brain size, but the function of Akt3 is not clear (Tschopp, Yang et al. 2005). 
PROTEIN PHOPHATASE 
As a living system, cells need to response to the changing environment and 
different stresses quickly and efficiently. Different signaling pathways are the ways that 
cell using to archive this homeostasis interaction between cells and extracellular 
environment. Phosphorylation and dephosphorylation of proteins play important roles in 
extracellular signal transducing from outside into nucleus since they are the quickest 
reaction for cells to response to the extracellular signals; adding and removing the 
phosphate group on a certain protein are used as a molecular switch to present on and 
off. Consistent to the important roles of phosphorylation and dephosphorylation in 
biophysical process, one third proteins in the total proteome have multiple 
phosphorylation sites which can be targeted by different kinase and phosphatase. 
Contrary to kinase which can phosphorylate proteins, phosphatase works as an 
antagonist to kinase through removing the phosphate group on target proteins added by 
specific kinase.     
There are about 147 genes in human genome encoding protein phosphatases and 
these protein phosphatases are classified into three major families which include protein 
tyrosine phosphatases (PTPs), serine/threonine phosphatases (S/TPs) and dual-
specificity protein phosphatases (DUSPs) based on the substrate preference (Barford, 
Das et al. 1998; Cohen 2003; Alonso, Sasin et al. 2004). In a total of 147 protein 
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phosphatases, there are around 38 protein tyrosine phosphatases, 40 serine/threonine 
phosphatases and 69 dual-specificity protein phosphatases (Barford, Das et al. 1998; 
Cohen 2003; Alonso, Sasin et al. 2004). Since most of the important modification sites 
of FoxO proteins are serine/threonine sites, serine/threonine phosphatases may play 
important for FoxO proteins activity regulation.  
According to the amino acid sequence and catalytic domain structure, S/TPs are 
further categorized into three subfamilies: phosphor-protein phosphatase (PPPs), 
magnesium/manganese-dependent protein phosphatase (PPMs/PP2Cs), and small C-
terminal domain phosphatase (FCPs) (Shi 2009). There are about 18 PPPS, 20 
PPMs/PP2Cs and 7 FCPs. PPP is consisted by a highly conserved catalytic subunit 
associated with additional regulatory subunits which are in charge of the subcellular 
localization and substrate specificity of the whole enzymes. PPP can dephosphorylate 
different substrates and play different roles in different cells and tissues with the flexible 
combination of catalytic subunits and regulatory subunits. The PPMs/PP2Cs are 
monomeric and normally contain a conserved catalytic domain. The activity of these 
enzymes depends on the binding of bivalent cation (Mg2+ or Mn2+). So far, there are 18 
PPMs/PP2C family members are discovered in mammalian, they are:  PPM1A (PP2Cα), 
PPM1B (PP2Cβ), PPM1D (wip1, PP2Cδ), PPM1E (POPX1, partner of Pix1), PPM1F 
(POPX2, partner of Pix2), PPM1G (PP2Cγ), PPM1H (NERRP-2C), PPM1J (PP2Cζ), 
PPM1K (PP2Cκ), PPM1L (PP2Cε), PPM1M (PP2Cη), PP2Cm, TA-PP2C (T-cell 
activation-PP2C), ILKAP (integrin-linked kinaseassociated PP2C), PHLPP1/2 (PH 
domain and leucine-rich repeat protein 1 and 2), and PDP1/2 (pyruvate dehydrogenase 
 14 
 
phosphatase isoenzyme 1 and 2). Given the diverse specificity and tissue/timing 
expression patterns, the PPMs/PP2Cs isoforms integrate into multiple signaling 
pathways regulation and participate in different biophysical processes (Lammers and 
Lavi 2007; Stern, Privman et al. 2007; Lu and Wang 2008). The first member was found 
in FCP family is FCP1 which dephosphorylates small C-terminal domain of RNA 
polymerase II (RNAPII) at serine 2/ 5 and plays important role in RNA transcription 
(Cho, Kim et al. 1999; Palancade, Dubois et al. 2001). SCP1 has similar function to 
dephosphorylate RNAP II but it prefers to affect serine 5 (Yeo, Lin et al. 2003). 
Interestingly, SCP1 was reported to be a transcription repressor which can inhibit 
neuronal genes expression through interacting with neuron-restrictive silencer factor 
(Yeo, Lee et al. 2005). Further studies showed that SCP1,2,3 can dephosphorylate 
Smad1 and 2/3 at C-terminal and linker region to affect TGFbeta and BMP signaling 
pathway (Sapkota, Knockaert et al. 2006; Wrighton, Willis et al. 2006). Epithelial-
mesenchyme transition (EMT) related transcription factor Snail was found to be the 
substrate of SCPs and dephosphorylating by SCPs can enhance Snail transcription 
activity in cells (Wu, Evers et al. 2009). The detailed roles and functions of SCP family 
members in different organs and physiological processes need to be further studied. 
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CHAPTER II   
IDENTIFICATION OF SMP5 AS A FOXO1/3A PHOSPHATASE 
INTRODUCTION 
Phosphorylation and dephosphorylation is an important part of the post-
transcriptional regulation of FoxO1/3a. Phosphorylating at different sites by different 
kinase can affect subcellular localization, protein stability and transcription activity. 
Among these events, Akt/PKB induced Serine256/253 phosphorylation of FxoO1/3a is 
the most important and primary modification for the insulin activated repression of 
FoxO1/3a. Phosphorylation of Serine256 is necessary for sequentially phosphorylation 
of Threonine24 (Rena, Prescott et al. 2001). After phosphorylated by Akt/PKB at 
Serine319, a consensus binding sequence is created for casein kinase 1 which can in turn 
phosphorylate FoxO1 at serine322 and 325 to facilitate FoxO1 cytoplasm localization 
(Rena, Woods et al. 2002). Given the role of Serine 256/253 phosphorylation of 
FoxO1/3a, it is important to identify the phosphatases which can dephosphorylate at 
serine 256/253 and in turn regulate transcription activity in different cell types and 
different physiological processes.  A dual-specificity phosphatase MKP3 was reported to 
be a FoxO1 phosphatase which can dephosphorylate FoxO1 in cytoplasm and in turn 
regulate FoxO1 transcription activity on gluconeogenesis related genes. PP2A also was 
found to be a phosphatase of FoxO1/3a. It affects function in cell apoptosis through 
dephosphorylating FoxO1/3a (Yan, Lavin et al. 2008; Wu, Jiao et al. 2010). The 
question is raised that whether there are nuclear localized phosphatases which can 
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dephosphorylate and then modulate gluconeogenesis. From the diabetes database we 
found that the expression of SMP5, a member of small c terminal phosphatase family, is 
regulated during mouse metabolism profile changing (Keller, Choi et al. 2008). The 
expression change of SMP5 suggests that SMP5 may play roles in metabolism. We 
proposed that SMP5 is a potential nuclear localized FoxO proteins phosphatase. To 
verify the hypothesis, first of all we checked the SMP5 expression profile in wild type 
C57BL mice undergoing fasting and feeding cycle. The subcellular localization also be 
revealed by using cell fractionation and subcellular localiztion with exogenous GFP 
tagged SMP5 protein. To further confirm the role of SMP5 as a phosphatase for FoxO 
proteins, in vivo and in vitro phosphorylation assay were applied to study the SMP5 
phosphatase activity. 
MATERIALS AND METHODS 
MOUSE 
8 C57BL mice were randomly separated into 4 groups. One group was fed with 
regular diet feeding, one group was fasted for 12 hours, one group was fasted for 24 
hours and the last group was fasted 24 hours followed with 12 hours re-feeding. After 
treatment, the mice were sacrificed. Mouse liver was dissected out for protein and RNA 
extraction. All protocols are approved by the Institutional Animal Care and Use 
Committee (IACUC). For protein sample, the liver was homogenized in cold RIPA 
buffer with protease inhibitor and centrifuged with 12,000 rpm for 10 minutes at 4°C. 
The supernatant was kept and the concentration was measured with Bio-Rad protein 
assay kit (Cat#500-0001). For RNA sample, the liver was homogenized in 1ml cold 
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Trizol solution and kept at room temperature for 5 minutes to complete dissociate 
nucleoprotein complexes. 200μl chloroform was added into tube and mixed well with 
shaking tube vigorously by hand for 15 seconds. The mixture was incubated at room 
temperature for 2 to 3 minutes. Then the sample was centrifuged with 12,000g for 15 
minutes at 4°C. Supernatant was collected and 0.5ml isopropyl alcohol was added to 
precipitate total RNA. After spin down, the pellet was washed with 70% EtOH and re-
suspended with DEPC water. The RNA concentration was measured with spectrometry. 
CELL CULTURE AND TRANSFECTION 
Cell culture and transfection were essentially performed as previously described 
(Duan et al., 2006; Lin et al., 2006). HEK 293T cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM, Invitrogen, Cat # 11965-092) with 10% fetal bovine 
serum (FBS, Invitrogen, Cat # 16000-044). HepG2 cells were cultured in EMEM with 
10% fetal bovine serum and NEAA. NIH3T3 cells and HeLa cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, Cat # 11965-092) with 5% 
fetal bovine serum (FBS, Invitrogen Cat # 16000-044). In gene expression experiments, 
cells were transfected using Lipofectamine LTX (Invitrogen, Cat # 15338-030) and Plus 
(Invitrogen, Cat # 11514-015) Reagents or Lipofectamine 2000 (Invitrogen, Cat # 
11668-500) in Opti-MEM I Reduced Serum Medium (Invitrogen, Cat # 31985-062) as 
manufacturer’s instruction (Invitrogen). For transit expression, the HeLa cells were 
transfected using Lipofectamin LTX and Plus and harvested 36-48 hours after 
transfection. For knock down stable cell line, the HepG2 cells were transfected with 
pRight-shSMP5-1475 and screened with 1:1000 diluted puromycin (final concentration 
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2 ng/mL) 48hours after transfection. Knock down efficiency was verified by Western 
blotting and qPCR. For immuno-staining, NIH3T3 cells were transfected with pXF-
GFP-SMP5 using Lipofectamin 2000 and cells were fixed with 4%PFA for microscopy 
imaging.  
CELL FRACTIONATION 
HepG2 cells were trypsinized and washed with PBS pH7.4. The cells pellet was 
suspended with 300 μl buffer A ((250 mM Sucrose, 20 mM HEPES pH7.4, 10 mM KCl, 
1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA and 1mM DTT) including protease 
inhibitors and kept on ice for 10 minutes. The nuclear pellet was obtained by 
centrifuging at 1200 g for 5 minutes at 4°C . The supernatant was collected and kept as 
the cytoplasmic fraction.  The nuclear pellet was washed twice with 500 μl buffer A and 
then was suspended in buffer B (standard lysis buffer with 10% glycerol and 0.1% SDS 
added), lastly sonicated briefly (3 seconds) on ice at a power setting of 2-continuous. 
EXPRESSION AND KNOCK DOWN PLASMIDS 
HA tagged 14-3-3ζ was gotten from Dr.Dihua Yu’s laboratory. Human FoxO1/3a 
cDNA were obtained from Dr.Qiang Tong’s laboratory and were re-cloned into the 
pXF6F (a derivative of the CMV-driven expression vector pRK5, Genentech) vector 
with an N-terminal Flag tag at BamHI (5’) /SalI(3’) sites and BamHI(5’)/HindIII(3’) 
sites respectively. The human SMP5 wild type and point mutant (D295N) were cloned 
into pGTK5XF (a derivative of the GST fusion protein expression vector pGEX) and 
The human SMP5 wild type, DN mutant, C-terminal and N-terimnal deletion mutants 
were also cloned into pRK5 vector (Lin et al., 2006) with Flag, Myc, HA, GFP tag 
 19 
 
respectively. The shRNA plasmid against mouse and human SMP5: pRight-shSMP5-
1475 (target sequence GAGACAGATTTCGCTTGCATGATTT) in pRight vector (a 
derivative of the pSRG vector) was generated. A pair of DNA oligos (Table 2.1) was 
annealed with Bgl2 and Sal1 sites at two ends. The annealed double stranded oligo was 
cloned into linearized pRight Vector at Bgl2 and SalI sites.  
DNA PRIMERS  
All DNA primers (Table 2.1) were purchased from Sigma which were 
synthesized at a 0.2 μmol scale with the standard desalt purification. 
QPCR 
For each reaction, 1 μg total RNA was used as template. qScript™ cDNA 
SuperMix kit (Quanta Cat# 95048-100)  was used for reverse transcription. 20X diluted 
cDNA was used to be the template for qPCR. qPCR was performed with PerfeCTa® 
SYBR® Green SuperMix kit (Quanta Cat# 95054-500) by using 18S as internal control. 
IN VITRO PHOSPHORYLATION ASSAY 
Recombinant Glutathione S-transferase (GST) fused SMP5 wild type and DN 
point mutant proteins were generated by purifying the bacterially expressed GST fusion 
proteins according to manufacturer’s manual (Amersham Biosciences). Briefly, 
pGTK5XF-SMP5 WT/DN were transformed into BL21, the bacteria were induced by 
0.5mM isopropyl-β D-thiogalactoside (IPTG) when it reach the mid-log phase 
(A600=0.6~1.0). After 3~5 hours induction, the bacteria were harvest and lysed by GST   
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Table 2.1 DNA primers and oligos sequence 
Oli
go#  
Name purpose sequence 
1 qSMP5-F qPCR GCTGGTAGTTATGAAATGACAAAT  
2 qSMP5-R qPCR GTTGAAGACAGGCGAAAATATGG 
3 qPEPCK1
-F 
qPCR TGTCGGAAGAGGACTTTGAGA 
4 qPEPCK1
-R 
qPCR CACATAGGGCGAGTCTGTCA 
5 q18S-F qPCR ATTGACGGAAGGGCACCACC 
6 q18S-R qPCR GCCAGAGTCTGTTCGTTATC 
7 qGys1-F qPCR TTGGAAGACTGGGAGGATGA 
8 qGys1-R qPCR CATTCATCCCCTGTCACCTT 
9 qGys2-F qPCR GCTGAAAGACTCCCTGTGGA 
10 qGys2-R qPCR AATTCTCTCCCCACTCATCG 
11 qG6pc1-F qPCR TCGGAGACTGGTTCAACCTC 
12 qG6pc1-R qPCR ACAGGTGACAGGGAACTGCT 
13 qCRTC2-
F 
qPCR CTTCGAGGAGGTGATGATGG 
14 qCRTC2-
R 
qPCR AACATTGGGCAGAGAACCAC 
15 qHNF4a-F qPCR AAATGTGCAGGTGTTGACCA 
16 qHNF4a-
R 
qPCR CTCGAGGCTCCGTAGTGTTT 
17 qFoxo1 qPCR ACGAGTGGATGGTGAAGAGC 
18 qFoxo1 qPCR TGCTGTGAAGGGACAGATTG 
19 qFoxo3a qPCR ACAAACGGCTCACTTTGTCC 
20 qFoxo3a qPCR CTGTGCAGGGACAGGTTGT 
21 qMKP3-F qPCR ATCACTGGAGCCAAAACCTG 
22 qMKP3-R qPCR CATGAGGTACGCCACTGTCA 
23 SMP5-a-F In situ GGGGTACCCCTGCCAGAGCAAAGAGGAAAT 
24 SMP5-a-R In situ CGAGCTCGGTTCTTGGTGTTGATGTG 
25 SMP5-
KD-F 
SMP5 KD GATCTTCGAGACAGATTTCGCTTGCATGATTTTTGG 
AAATCATGCAAGCGAAATCTGTCTCTTTTTC 
26 SMP5-
KD-R 
SMP5 KD TCGAGAAAAAGAGACAGATTTCGCTTGCATGATTT
CCAAAATCATGCAAGCGAAATCTGTCTCGAA 
27 1.5K 
PEPCK1p
romoter 
PEPCK1  GGGGTACCTAGCTCTTCACACAGCTTTG 
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Table 2.1 Continued 
Olig
o#  
Name purpose sequence 
28 1.5K 
PEPCK1pro
moter 
PEPCK1  GAAGATCTATATAGAAGGGAGGACAGCC 
29 1.5K 
G6paseprom
oter 
G6PC  CGACGCGTCTAGTCACATGACACCAGC 
30 1.5K 
G6paseprom
oter 
G6PC  GAAGATCT TCCTCCCTTGGTACCTCAG 
31 cDNA 
hFoxO1-F 
hFoxO1c
DNA 
CGGGATCCTATGGCCGAGGCGCCTCAG 
32 cDNA 
hFoxO1-R 
hFoxO1c
DNA 
ACGCGTCGACTCAGCCTGACACCCAGCTA 
33 cDNA 
hFoxO3a-F 
hFoxO3ac
DNA 
CGGGATCCTATGGCAGAGGCACCGGCT 
34 cDNA 
hFoxO3a-R 
hFoxO3ac
DNA 
CCCAAGCTTCAGCCTGGCACCCAGCT 
35 FoxO1 SA-F  FoxO1 
mutation 
AGAGCTGCAGCCATGGACAA 
36 FoxO1 SA-R  FoxO1 
mutation 
TTGTCCATGGCTGCAGCTCT 
37 FoxO1 SD-F  FoxO1 
mutation 
AGAGCTGCAGACATGGACAA 
38 FoxO1 SD-R  FoxO1 
mutation 
TTGTCCATGTCTGCAGCTCT 
39 FoxO3a SA-
F  
FoxO3a 
mutation 
GGCTGTCGCCATGGACAATA 
40 FoxO3a SA-
R  
FoxO3a 
mutation 
TATTGTCCATGGCGACAGCC 
41 FoxO3a SD-
F  
FoxO3a 
mutation 
GGCTGTCGACATGGACAATA 
42 FoxO3a SD-
R  
FoxO3a 
mutation 
TATTGTCCATGTCGACAGCC 
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lysis buffer (10mM Tris-HCL pH7.5, 150mM NaCl, 1mM EDTA, 1% NP40). The GST 
fusion proteins were purified with Glutathione sephanose 4B beads (GE). 
Flag tagged FoxO1/3a proteins were generated by using TNT in vitro translation 
kit (Promega) and purified by pulling down with Flag antibody conjugated protein A-
sepharose beads. Briefly, 1μg pXF6F DNA templates were added into the TNT reaction 
mixture which contains TNT reaction buffer, rabbit reticulocyte lysate, T7 polymerase, 
amino acid mixture and RNAase inhibitor. The fully mixed reaction systems were 
incubated in 30°C for 1.5 hours and followed by Flag beads pull down purifying. The 
purified proteins were phosphorylated at serine256/253 by in vitro phosphorylating with 
purified Akt (Sigma). After phosphorylated by Akt, the Flag beads banded proteins were 
spun down again and washed with in vitro phosphatase buffer (40 mM Tris-HCl pH 8.0, 
20 mM KCl and 2 mM dithiothreitol, 30 mM MgCl2) to remove the Akt reaction buffer. 
The phosphorylated FoxO1/3a proteins bound beads were suspended with in 
vitro phosphatase buffer and aliquoted into three Eppendorf tubes. Equal amount of GST 
only, GST-SMP5 WT and GST-SMP5 DN were added into the tubes and the reaction 
systems were incubated in 37°C for 1 hour followed by boiling with 2X SDS loading 
dye. 
ANTIBODIES 
Antibody against Flag tag was from Kodak, Myc tag (9E10, Cat#05-419) from 
EMD, HA tag from Babco and GFP from Invitrogen. Antibodies against pSerine256-
FoxO1 (Cat# 9461) and pSerine253-FoxO3a (Cat#9466) were purchased from Cell 
Signaling Technology. Antibody against α-tubulin, β-actin and GAPDH were from 
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Sigma. Antibody against SMP5 was generated from rabbit by using N-terminal of SMP5 
and validated by our laboratory. 
RESULTS AND DISCUSSION 
We first tested whether SMP5 expression level is changed in wild type mouse 
liver during fasting-feeding cycle. C57BL mice were starved for 24 hours and re-feed for 
12 hours. For time zero, 12 hours fasting, 24 hours fasting and 12 hours re-feeding, 2 
mice were sacrificed and the SMP5 protein and mRNA level were checked by using 
western blotting. Western blotting showed that during starvation the SMP5 protein 
increased and after re-feeding the expression of SMP5 went back to the normal level 
(Figure 2.1). 
Next we checked the subcellular localization of SMP5. Cellular fractionation was 
applied to HepG2 cells. The western blotting showed that SMP5 is exclusively localized 
in cell nucleus (Figure 2.2). Consist to the fractionation experiment, GFP signal can only 
be found in the nucleus after transfecting with GFP SMP5 fusion protein in NIH3T3 
cells. All the data suggests that SMP5 is a nuclear localized protein (Figure 2.3). 
To investigate whether SMP5 can affect FoxO1/3a phosphorylation level in cell, 
pXFGFP empty vector, pXF6F SMP5 wild type and pXF6F SMP5 DN mutant were 
transfected into HeLa cells, 24 hours after transfection serum free DMEM medium was 
used to replace the regular medium for 12 hours culture. 30 minutes before harvesting 
the cell with 2X SDS loading dye, the serum free medium was changed to 0.2%FBS 
DMEM medium. The cells lysate were subjected to western blotting, α-tubulin, β-actin, 
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total FoxO1, total FoxO3a, phospho-FoxO1, phospho-FoxO3a, GFP and Flag tagged 
SMP5 were detected by using anti- α-tubulin, anti-β-actin, anti-FoxO1, anti-FoxO3a, 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Endogenous SMP5 protein level changes in mouse liver during 
fasting/feeding cycle. C57BL mice were starved for 24 hours and re-feed for 12 hours. 
Mouse was sacrificed at four time points (Fasting 0 hour, Fasting 12 hours, Fasting 24 
hours and Fasting 24 hours plus re-feeding 12 hours). Livers were lysed with RIPA 
buffer and subjected to western blotting using SMP5, β-actin and GAPDH antibodies as 
indicated.  
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Figure 2.2 Endogenous SMP5 locates in cell nucleus. HepG2 cells were harvested and 
subjected to cellular fractionation. Whole cell lysate, cytoplasm and nuclear extraction 
were subjected to western blotting using SMP5, Histone3, α-tubulin, β-actin and 
GAPDH antibodies as indicated. 
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Figure 2.3 GFP tagged SMP5 locates in nucleus of NIH3T3 cells. GFP and GFP 
tagged SMP5 were transfected into NIH3T3 cells. 36 hours after transfection, cells were 
fixed with 4% PFA and taken pictures with fluorescence microscope. The GFP SMP5 
fusion protein can only be detected in nucleus.  
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anti-phospho-FoxO1, anti-phospho-FoxO3a, anti-GFP and anti-Flag antibodies 
respectively. SMP5 knock down stable cell line was also used to verify the role of SMP5 
on FoxO1/3a dephosphorylating.  HepG2 SMP5 knock down and control cells were 
cultured in serum free EMEM medium overnight and replaced the medium to 0.2% FBS 
EMEM medium for 30 minutes.  The cells were harvest with 2X SDS loading dye and 
cells lysates were subject to western blotting by using anti-α-tubulin, anti-β-actin, anti-
FoxO1, anti-FoxO3a, anti-phospho-FoxO1, anti-phospho-FoxO3a and anti-SMP5 
antibodies. The western blotting data showed that overexpressing SMP5 wild type can 
decrease phosphorylation level of endogenous FoxO1/3a but SMP5 DN mutant cannot 
affect it (Figure 2.4 and Figure 2.5). On the contrary, the phosphorylation level of 
endogenous FoxO1/3a was increased SMP5 knock down HepG2 cell line comparing to 
control cell line (Figure 2.6). These results suggest that SMP5 has effect on the 
phosphorylation level of FoxO1/3a.  
Since manipulating SMP5 in cell can affect FoxO1/3a phosphorylation status, to 
further confirm the effect of SMP5 on FoxO1/3a is direct or indirect we studied whether 
SMP5 can dephosphorylate FoxO1/3a in vitro. Flag tagged FoxO1/3a were generated by 
using TNT in vitro translation system. After phosphorylated by commercially purchased 
Akt, the phosphor-FoxO1 and phospho-FoxO3a were mixed and incubated with GST-
SMP5 WT and GST-SMP5 DN purified from bacteria. Reaction products were subjected 
to western blotting with the antibody specific for the phospho-serine256 of FoxO1 and 
phospho-serine253 of FoxO3a. As shown in Figure 2.7, Akt induced the phosphorylation 
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Figure 2.4 SMP5 dephoshorylates FoxO1 in HeLa cells. Flag tagged SMP5 wild type 
and DN mutant were transfected into HeLa cells. 24 hours after transfection serum free 
DMEM medium was used to replace the regular medium for 12 hours culture. 30 
minutes before harvesting the cell with 2X SDS loading dye, the serum free medium was 
changed to 0.2%FBS DMEM medium. The cells lysate were subjected to western 
blotting using α-tubulin, β-actin, total FoxO1, phospho-FoxO1, GFP and Flag antibodies 
as indicated.  
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Figure 2.5 SMP5 dephoshorylates FoxO3a in HeLa cells. Flag tagged SMP5 wild type 
and DN mutant were transfected into HeLa cells. 24 hours after transfection serum free 
DMEM medium was used to replace the regular medium for 12 hours culture. 30 
minutes before harvesting the cell with 2X SDS loading dye, the serum free medium was 
changed to 0.2%FBS DMEM medium. The cells lysate were subjected to western 
blotting using α-tubulin, β-actin, total FoxO3a, phospho-FoxO3a, GFP and Flag 
antibodies as indicated.  
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Figure 2.6 Phosphorylation FoxO1/3a is increased in SMP5 knockdown HepG2 
stable cells. HepG2 SMP5 knockdown and control cells were cultured in serum free 
EMEM medium overnight and replaced the medium to 0.2% FBS EMEM medium for 
30 minutes.  The cells were harvest and subjected to western blotting using α-tubulin, β-
actin, total FoxO1, phospho-FoxO1, total FoxO3a, phospho-FoxO3a and SMP5 
antibodies as indicated. 
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Figure 2.7 In vitro translated FoxO1/3a is phosphorylated by Akt. Flag tagged 
FoxO1/3a was translated with TNT system and pulled down with anti-Flag antibody 
conjugated protein A beads. Purified FoxO1/3a was incubated with Akt in Akt kinase 
reaction buffer and subjected to western blotting using phospho-FoxO1, phospho-
FoxO3a and Flag antibodies as indicated. 
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of FoxO1/3a (indicated by the phospho-FoxO1 and phospho-FoxO3a level). SMP5 
attenuated the Akt induced phospho-FoxO1 and phospho-FoxO3a level (Figure 2.8 and 
Figure 2.9). On the other hand, SMP5 DN mutant which is a phosphatase function null 
mutant cannot attenuate the Akt induced phospho-FoxO1 and phospho-FoxO3a level. 
Equal level of total Flag tagged FoxO1/3a proteins in each sample were confirmed by 
immune-blotting with the anti-Flag antibody. These results suggest that SMP5 can 
dephosphorylate FoxO1/3a directly and the effect of SMP5 on FoxO1/3a 
phosphorylation is related to the phosphatase activity of SMP5. 
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Figure 2.8 SMP5 wild type protein directly dephosphorylates FoxO1. Equal amount 
of Akt treated FoxO1 was incubated with GST, GST SMP5 fusion protein and GST 
SMP5 DN mutant fusion protein respectively in phosphatase reaction buffer. After 
incubation, products were washed and subjected to western blotting using phospho-
FoxO1, Flag and GST antibodies as indicated. 
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Figure 2.9 SMP5 wild type protein directly dephosphorylates FoxO3a. Equal amount 
of Akt treated FoxO3a was incubated with GST, GST SMP5 fusion protein and GST 
SMP5 DN mutant fusion protein respectively in phosphatase reaction buffer. After 
incubation, products were washed and subjected to western blotting using phospho-
FoxO3a, Flag and GST antibodies as indicated. 
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CHAPTER III   
SMP5 INTERACTS WITH FOXO1/3A IN VITRO AND IN VIVO 
INTRODUCTION 
Previous results suggested SMP5 can dephosphorylate in vitro and in vivo. The 
next question was whether SMP5 can interact with FoxO1/3a or not. To check the 
possibility of physical interaction between SMP5 and FoxO1/3a, Co-
Immunoprecipitation and were applied. We found that SMP5 can be pulled down by 
using FoxO1 or FoxO3a as the bait and using anti-SMP5 antibody can also precipitate 
endogenous FoxO1/3a. Furthermore, the in vitro binding assay results showed that 
FoxO1/3a can bind to SMP5 directly.  
MATERIALS AND METHODS 
CO-IMMUNOPRECIPITATION ASSAY 
HA tagged SMP5 and Flag tagged FoxO1 or FoxO3a were co-transfected into 
HEK293 cells. Transfected cells were harvested and lysed by 20% glycerol lysis buffer 
after 36 hours. The cell lysates were pre-cleaned with protein A beads and then 
incubated with Flag antibody conjugated protein A beads at 4°C and rotated overnight. 
After overnight incubation, beads were washed with Flag lysis buffer for 3 times. For 
endogenous CoIP, one 10mm dish 293T cells were starved with serum free medium for 
overnight, after starvation the cells were collected and suspended in pre chilled buffer A 
with protease inhibitor cocktail (aprotinin, leupeptin, and phenylmethylsulfonyl fluoride) 
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and phosphatase inhibitors (NaF, Na3VO4)to remove the cytoplasm. The remaining 
nucleus was lysed in 1ml RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% 
NP-40, 0.25% sodium deoxycholate) with protease inhibitor cocktail (aprotinin, 
leupeptin, and phenylmethylsulfonyl fluoride) and phosphatase inhibitors (NaF, 
Na3VO4). After pre-cleaned with 20μl protein A beads, the lysate was aliquoted into 
two eppendorf tubes and incubate with IgG and anti-SMP5 respectively overnight at 
4°C. the antibodies associated complexes were pulled down with 20 μl protein A beads 
and washed with RIPA buffer for 3 times. The IP products were subjected to western 
blotting.  
IN VITRO BINDING ASSAY 
Recombinant Glutathione S-transferase (GST) fusion proteins were generated by 
purification of bacterially expressed GST fusion protein per manufacturer’s instruction 
(Amersham Biosciences). In vitro-translated (TNT kit; Promega) Flag tagged proteins 
were pre-cleared with 5 μg of GST protein for 1 h then were incubated with 5 μg of 
different GST fusion proteins for 2 h in the in vitro binding buffer (50 mM Tris-HCl pH 
7.5, 120 mM NaCl, 2 mM EDTA, 0.1% NP-40), with protease inhibitor cocktail 
(aprotinin, leupeptin, and phenylmethylsulfonyl fluoride) and phosphatase inhibitors 
(NaF, Na3VO4). After extensively washed with the in vitro binding buffer proteins 
bound to GST fusion proteins were isolated with glutathione-Sepharose beads 
(Amersham Pharmacia Biotech), separated by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE), the target proteins were detected with anti-Flag and 
anti-GST antibodies. 
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RESULTS AND DISCUSSION 
Previous data showed that SMP5 can dephosphorylate FoxO1/3a within cells and 
in vitro. The remaining question was whether there is directly interaction between SMP5 
and FoxO1/3a since a physical interaction is required for enzyme and its substrates. To 
answer this question, Co-immunoprecipitation was used to verify the interaction between 
SMP5 and FoxO1/3a. We found immunoprecipitation using anti-Flag antibody not only 
retrieved Flag tagged FoxO1/3a, but also HA tagged SMP5 which associated with 
FoxO1 or FoxO3a. As a negative control, without co-transfection of Flag tagged FoxO1 
or FoxO3a, the anti-Flag antibody cannot pull down HA tagged SMP5 (Figure 3.1 and 
Figure 3.2). Vice versa, beside SMP5 itself, immunoprecipitation using anti-SMP5 
antibody can also pull down SMP5 associated FoxO1/3a in 293T cells (Figure 3.3). CoIP 
data suggests there is interaction between SMP5 and FoxO1/3a in cells. To further 
confirm whether the interaction between SMP5 and FoxO1/3a is direct, the GST-pull 
down assay was used and we found that SMP5 GST fusion protein can pull down the 
Flag tagged FoxO1/3a, but GST protein alone cannot (Figure 3.4 and Figure 3.5). This 
result suggests the interactions between SMP5 and FoxO1/3a are directly. 
In summary, these results indicated that SMP5 directly interact with FoxO1/3a. 
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Figure 3.1 SMP5 co-immunoprecipitates with FoxO1. HEK293T cells were 
transfected with indicated expression plasmids for HA tagged SMP5 and Flag tagged 
FoxO1. FoxO1 or FoxO1 bound SMP5 was detected by anti-HA Western blotting 
analysis of the anti-Flag immunoprecipitation (IP). 
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Figure 3.2 SMP5 co-immunoprecipitates with FoxO3a. HEK293T cells were 
transfected with indicated expression plasmids for HA tagged SMP5 and Flag tagged 
FoxO3a. FoxO3a or FoxO3a bound SMP5 was detected by anti-HA Western blotting 
analysis of the anti-Flag immunoprecipitation (IP). 
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Figure 3.3 SMP5 interacts with endogenous FoxO1/3a. HEK 293T cells were 
subjected to anti-SMP5 IP. SMP5 bound FoxO1/3a were detected by anti-FoxO1 and 
anti-FoxO3a western blotting. Rabbit IgG was used as the control (lane 1).  
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Figure 3.4 SMP5 directly interacts with FoxO1 in vitro. The pull down of in vitro 
translated Flag tagged FoxO1 by GST-SMP5, GST only as a negative control.  
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Figure 3.5 SMP5 directly interacts with FoxO3a in vitro. The pull down of in vitro 
translated Flag tagged FoxO3a by GST-SMP5, GST only as a negative control.  
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CHAPTER IV  
SMP5 FACILITATES FOXO1/3A NUCLEUS LOCALIZATION 
INTRODUCTION 
Phosphorylation and dephosphorylation events play important roles in the post-
transcriptional regulation of FoxO1/3a. There are multiple kinases can phosphorylate 
FoxO1/3a at different sites which in turn affect FoxO1/3a in different ways such as 
subcellular localization, protein stability and transcription activity. Among these 
modifications, Akt/PKB induced serine256/253 phosphorylation of is the most important 
and primary action for the insulin activated repression of FoxO1/3a through exporting 
FoxO1/3a from nucleus to cytoplasm. (A31)  Since SMP5 can interact with FoxO1/3a 
and dephosphorylate FoxO1/3a at serine256/253 respectively, we further studied 
whether SMP5 can affect FoxO1/3a subcellular distribution and how it can achieve this 
result. 
MATERIALS AND METHODS 
IMMUNOSTAINING 
NIH3T3 cells grew on cover slips were transfected with three plasmid 
combinations including Flag tagged FoxO1/3a plus GFP vector, Flag tagged FoxO1/3a 
plus GFP tagged SMP5 wild type and Flag tagged FoxO1/3a plus GFP tagged SMP5 DN 
mutant. 12 hours after transfection, the culture medium was replaced with serum free 
DMEM for overnight to remove the basal level insulin-Akt signal. Then, the starvation 
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medium was replaced by regular DMEM medium for 30 minutes. The cells were washed 
with PBS pH7.4 and fixed with 4%PFA. The fixed cells were washed with PBS for 3 
times and permeabilized with 0.5% Triton X-100 in PBS for 10 minutes. Followed 
permeabilization, the cells were washed again with PBS and blocked with 5% fat free 
milk in PBS with 0.1% Triton X-100. After blocking, the cells were blotted with 1:300 
diluted mouse anti-GFP and rabbit anti-Flag antibodies at 4°C overnight. FITC 
conjugated anti-mouse and Texas Red conjugated anti-rabbit secondary antibodies were 
applied after the cells washed with PBS with 0.1% Triton X-100 for 3 times. Cover slips 
were mounted with DAPI contained mounting buffer and took pictures with fluorescence 
microscopy.   
CO-IMMUNOPRECIPITATION ASSAY 
Myc tagged SMP5 wild type or DN mutant were co-transfected with Flag tagged 
FoxO1/3a and HA tagged 14-3-3ζ.  Anti-Flag antibody conjugated protein A beads were 
used to pull down FoxO1/3a and their associated 14-3-3 ζ as the protocol describe 
previously. The IP products were analyzed by western blotting with anti-Flag, anti-Myc 
and anti-HA antibodies. 
RESULTS AND DISCUSSION 
As the primary and most important phosphorylation sites of FoxO1/3a, serine 
256/253 phosphorylation can repress FoxO1/3a transcription activity through inducing 
their nucleus export (Nakae, Park et al. 1999; Van Der Heide, Hoekman et al. 2004).  
Since SMP5 was found to be a potential nucleus localized phosphatase of FoxO1/3a, we 
first tested whether SMP5 can affect FoxO1/3a subcellular distribution. The 
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immunostaining data showed FoxO1/3a were transported into nucleus with serum 
deprivation treatment (Figure 4.1 and Figure 4.2 ), after replacing the serum starvation 
medium with regular medium, only the FoxO1/3a co-transfected with SMP5 wild type 
can be sustained inside the nucleus at a high ratio. Contrast to wild type SMP5 but 
similar to the vector control, the DN mutant did not affect the subcellular distribution of 
FoxO1/3a (Figure 4.1, Figure 4.2, Figure 4.3 and Figure 4.4). The immunostaining data 
demonstrated that SMP5 can facilitate FoxO1/3a to sustain inside the nucleus. The 
SMP5 DN mutant failed to keep FoxO1/3a in the nucleus suggests the nucleus 
localization caused by SMP5 wild type co-transfection due to its phosphatase activity.  
The phosphorylation induced 14-3-3ζ binding to FoxO1/3a are required for the 
nucleus export of FoxO1/3a (Rena, Prescott et al. 2001; Brunet, Kanai et al. 2002; 
Tzivion, Dobson et al. 2011). We further investigated the function of SMP5 on 
FoxO1/3a and 14-3-3ζ interaction by using CoIP approach. We found that the interaction 
between FoxO1/3a and 14-3-3ζ was disrupted when SMP5 wild type presents but not 
SMP5 DN mutant (Figure 4.5 and Figure 4.6). This data suggests the phosphatase 
activity of SMP5 is important for the function by what the interaction was affected. This 
disruption may due to the 14-3-3ζ masked NLS is exposed which is caused by releasing 
of 14-3-3ζ after dephosphorylating FoxO1/3a.  
In summary, SMP5 can enhance FoxO1/3a nucleus sustaining through disrupting 
FoxO1/3a, 14-3-3ζ interaction. 
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Figure 4.1 SMP5 facilitates FoxO1 nucleus sustaining with serum treatment. Flag 
tagged FoxO1 (Red) and GFP tagged SMP5 wild type or SMP5 DN mutant (Green) 
were co-transfected into NIH3T3 cells. Serum starved cells were treated with 5%CS, the 
FoxO1 with SMP5 wild type co-transfection can be detected in nucleus. (Yellow arrow) 
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Figure 4.2 SMP5 facilitates FoxO3a nucleus sustaining with serum treatment. Flag 
tagged FoxO3a (Red) and GFP tagged SMP5 wild type or SMP5 DN mutant (Green) 
were co-transfected into NIH3T3 cells. Serum starved cells were treated with 5%CS, the 
FoxO3a with SMP5 wild type co-transfection can be detected in nucleus. (Yellow arrow) 
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Figure 4.3 SMP5 enhance FoxO1 nucleus sustaining. Cell numbers with nuclear Flag 
staining and with cytosol Flag staining were counted in Figure 4.1. Cell numbers with 
nuclear Flag signal is increased with SMP5 co-transfection. 
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Figure 4.4 SMP5 enhance FoxO3a nucleus sustaining. Cell numbers with nuclear Flag 
staining and with cytosol Flag staining were counted in Figure 4.2. Cell numbers with 
nuclear Flag signal is increased with SMP5 co-transfection. 
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Figure 4.5 SMP5 wild type, but not SMP5 DN mutant, affects FoxO1-14-3-3 ζ 
association. HEK293T cells were transfected with expression plasmids for Flagged 
tagged FoxO1, HA tagged 14-3-3 ζ and MYC tagged SMP5 WT/DN. 14-3-3 ζ bound 
FoxO1 was detected by anti-HA IP and anti-Flag western blotting. 
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Figure 4.6 SMP5 wild type, but not SMP5 DN mutant, affects FoxO3a-14-3-3 ζ 
association. HEK293T cells were transfected with expression plasmids for Flagged 
tagged FoxO3a, HA tagged 14-3-3 ζ and MYC tagged SMP5 WT/DN. 14-3-3 ζ bound 
FoxO3a was detected by anti-HA IP and anti-Flag western blotting. 
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CHAPTER V 
SMP5 ENHANCES FOXO1/3A TRANSCRIPTION ACTIVITY 
INTRODUCTION 
Phosphorylation and nucleus export of FoxO1/3a induced by Akt is the major 
process through which insulin inhibits FoxO1/3a transcription activity on 
gluconeogenesis related genes. (Biggs, Meisenhelder et al. 1999; Brunet, Bonni et al. 
1999; Kops, de Ruiter et al. 1999) SMP5 is shown to be the phosphatase of FoxO1/3a 
and it can facilitate FoxO1/3a nucleus localization. We next investigate whether SMP5 
can affect FoxO1/3a transcription activity on gluconeogenesis related genes. Two key 
downstream genes of FoxO1/3a, PEPCK1 and G6PC, were used to be our targets for the 
FoxO1/3a transcription activity study. To explore the potential of SMP5’s ability to 
affect FoxO1/3a transcription activity, luciferase reporter assay and glucose production 
assay approaches were applied. 
MATERIALS AND METHODS 
LUCIFERASE REPORTER ASSAY 
1.5kb mouse PEPCK1 promoter sequence was amplified from MEF cells 
genomic DNA extraction with Pfu high fidelity Taq (Promega) and cloned into pGL3-
basic luciferase reporter assay vector digested with KpnI and BglII. 1.5kb mouse G6PC 
promoter sequence was amplified from MEF cells genomic DNA extraction with Pfu 
high fidelity tag (Promega) and cloned into pGL3-basic luciferase reporter assay vector 
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digested with MluI and BglII. Different combination including PEPCK1/G6PC reporter 
alone, PEPCK1/G6PC reporter with FoxO1/3a, and PEPCK1/G6PC reporter with 
FoxO1/3a and SMP5 wild or DN mutant were transfected into NIH3T3 cells with 
lipofectamin 2000. pSV-β-gal (Promega), which expresses β-galactosidase driven by the 
simian virus 40 early promoter, was co-transfected as the transfection efficiency 
indicator used to normalize the luciferase activity reading. The amount of luciferase 
reporter plasmid DNAs used for transfection was 75ng/well and pSV-βgal was 
10ng/well (in a 12-well plate), addition vector DNA was add to make the total amounts 
of transfected DNA equal. 36 hours after transfection, cells were harvested and lysed 
with luciferase reporter lysis buffer (Promega). Centrifuging the lysates with 12,000rpm 
at 4°C for 10 minutes and measuring the luciferase and β-galactosidase activities by 
using reporter assay kit (Promega). All data sets were done with duplication and all 
values were normalized with β-galactosidase activities for transfection efficiency.  
GLUCOSE PRODUCTION ASSAY 
SMP5 knock down HepG2 stable and scramble control were used for glucose 
production assay. Briefly, 0.6 million HepG2 cells were seed in 12 wells plate one day 
before treatment. The day after cells seeding, 600μl glucose production medium (no 
glucose, no phenol red and serum free DMEM containing gluconeogenic substrates, 
20mM sodium lactate, and 2mM sodium pyruvate) was used to replace the regular 
medium with after 3 times wash with warm PBS and the cells were incubated for 13 
hours. Glucagon was added into the glucose production medium with the final 
concentration 100mM for extra 3 hours treatment. The medium was collected to measure 
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the glucose concentration with Amplex® Red Glucose/Glucose Oxidase Assay Kit 
(Invitrogen Cat# A22189) according to the product manual. The cells were lysed with 
RIPA for protein concentration measurement. The glucose concentration was normalized 
by protein concentration. 
RESULTS AND DISCUSSION 
PEPCK1 and G6PC are two key enzymes that play very important roles in 
gluconeogenesis (Hers and De Duve 1950; Chakravarty, Cassuto et al. 2005). During 
glucose homeostasis in animal, PEPCK1 and G6PC are regulated to response to the 
blood glucose flux. Insulin is the most important hormone which inhibits PEPCK1 and 
G6PC expression for the purpose of lowing blood glucose. Insulin-PI3K-Akt-FoxO axis 
is a major signal pathway which mediates PEPCK1 and G6PC expression. Akt down-
regulates PEPCK1 and G6PC expression through phosphorylating FoxO1/3a and in turn 
inhibiting their transcription activity. Consistent with the roles of FoxO1/3a as the 
transcription factors for PEPCK1 and G6PC, FoxO proteins binding sites were found on 
PEPCK1 and G6PC promoter regions (Durham, Suwanichkul et al. 1999; Schmoll, 
Walker et al. 2000; Altomonte, Richter et al. 2003; Vander Kooi, Streeper et al. 2003; 
Chakravarty, Cassuto et al. 2005). We cloned 1.5kb promoter region of PEPCK1 and 
G6PC which contain the FoxO proteins binding sites and studied the promoter activity of 
those genes in NIH3T3 cells which were transiently transfected with SMP5 wild type or 
SMP5 DN mutant. Based on luciferase assay, we found FoxO1 or FoxO3a alone can 
increase the luciferase signal comparing to the empty vector. Co-transfecting SMP5 wild 
type with FoxO1 or FoxO3a can further enhances the FoxO1/3a transcription activity. 
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SMP5 DN mutant does not affect FoxO1/3a function based on the readout (Figure 5.1 
and Figure 5.2). To confirm whether the enhanced transcription activity of FoxO 
proteins are directly related to the specific serine site or not, FoxO3a SA SD mutations 
were generated and co-transfected with SMP5. The data showed the FoxO3a SA mutant 
luciferase activity cannot be further enhanced by SMP5 since the SMP5 target site has 
been already mutated to unphosphorylatable status. The transcription activity of FoxO3a 
SD mutant was not repressed which is out of our prediction (Figure 5.3). The possible 
explanation is that serine 253 single site phosphorylation is not enough for the FoxO3a 
nucleus export. It is also reported that acetylation may override the phosphorylation 
induced nuclear export of FoxO1 (Frescas, Valenti et al. 2005). Furthermore, the SMP5 
also cannot significantly affect FoxO3a SD mutant transcription activity. Mutating the 
serine 253 site can abolish the enhancement of SMP5 on FoxO3a transcription activity 
suggests serine 253 is the key target of SMP5. The luciferase reporter assay suggests 
SMP5 can facilitate FoxO1/3a transcription activity on gluconeogenesis related genes 
and this enhance effect depends on the phosphatase activity of SMP5. 
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Figure 5.1 SMP5 enhances FoxO1 transcription activity. NIH3T3 cells were 
transfected with PEPCK1 (upper) and G6PC (down) reporter plasmid, FoxO1 and SMP5 
wild type and DN mutant. SV-βgal was used as an internal control. 36 hours after 
transfection, cells were harvested for measurement of luciferase and β-galactosidase 
activities. 
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Figure 5.2 SMP5 enhances FoxO3a transcription activity. NIH3T3 cells were 
transfected with PEPCK1 (upper) and G6PC (down) reporter plasmid, FoxO3a and 
SMP5 wild type and DN mutant. SV-βgal was used as an internal control. 36 hours after 
transfection, cells were harvested for measurement of luciferase and β-galactosidase 
activities. 
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Figure 5.3 SMP5 enhances FoxO3a transcription activity through 
dephosphorylating Serine 253. NIH3T3 cells were transfected with G6PC reporter 
plasmid, FoxO3a wild type, FoxO3a SA mutant (upper), FoxO3a SD mutant (down) and 
SMP5 wild type. SV-βgal was used as an internal control. 36 hours after transfection, 
cells were harvested for measurement of luciferase and β-galactosidase activities. 
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Given the important roles of PEPCK1 and G6PC in gluconeogenesis process 
(Lei, Shelly et al. 1993; Shelly, Lei et al. 1993; Chakravarty, Cassuto et al. 2005). The 
most important consequence of PEPCK1 and G6PC expression level changes is the 
affected glucose production (Veneziale, Donofrio et al. 1983; Liu, Barrett et al. 1994; 
Haber, Chin et al. 1995; Mosseri, Waner et al. 2000; Robinson, Dinulescu et al. 2000). 
To test whether SMP5 can affect gluconeogenesis through regulating FoxO1/3a’s 
transcription activity on PEPCK1 and G6PC, we applied cells based glucose production 
assay. The liver derived HepG2 cells were used to generate the SMP5 knockdown stable 
cell line.  After incubating with glucose production medium, the cells released glucose 
was measured and the glucose concentration was normalized with the protein 
concentration of the whole cell lysate. The data showed that SMP5 knockdown stable 
cell line produced less glucose compare to control cell line under the same condition 
(Figure 5.4).  
In summary, SMP5 can enhance FoxO1 and FoxO3 transcription activity on 
PEPCK1 and G6PC, and this ability is related to SMP5’s phosphatase activity. 
Knockdown SMP5 in HepG2 cells can significantly decrease the glucose production of 
HepG2 cells. The data supports that SMP5 plays important role in gluconeogenesis 
through FoxO1/3a. 
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Figure 5.4 Knocking down SMP5 represses HepG2 glucose production. HepG2 cells 
were treated with glucose production medium for 16 hours. 3 hours before measurement, 
glucagon was added into medium. Medium glucose concentration was measured and 
normalized by cell lysate protein concentration. (Left panel) SMP5 knock down 
efficiency was verified by western blotting. (Right panel) 
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CHAPTER VI  
GENERATING AND VALIDATING SMP5 KO MOUSE 
INTRODUCTION 
Cell based assays showed SMP5 can dephosphorylate FoxO1/3a and affect 
gluconeogenesis related genes expression. The SMP5 function in animal is needed to be 
further answered. Manipulating endogenous SMP5 level in mouse gave us an 
opportunity to understand the role of SMP5 in vivo. For this purpose, a SMP5 knockout 
mouse was generated by our laboratory by using plasmid purchased from KOMP with 
gene trap strategy (Gossler, Joyner et al. 1989). The deletion of SMP5 gene was 
validated with qPCR and western blotting. 
MATERIALS AND METHODS 
GENE TRAP MOUSE 
A lacZ gene contained cassette was inserted into the intron 2 of SMP5. The 
transcription terminator inside the insertion cassette can block the transcription of SMP5 
mRNA from genome after intron 2 (Figure 6.1).  
MEF CELLS ISOLATION 
Mouse embryonic fibroblast (MEF) cells were isolated from wild type and SMP5 
KO mouse embryos at developmental stage E12.5~E13.5. All protocols are approved by 
the Institutional Animal Care and Use Committee (IACUC) to maintain and use of 
laboratory animals. All equipment which contact with embryos and cells were 
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autoclaved and the solutions were filtered with 0.2μm membrane. MEF cells were 
isolated as following steps: 
1. Pregnant mice were sacrificed 12.5 to 13.5 days after plug was observed and the 
fetuses were dissected out. 
2. The tails of fetus were kept for genotyping. The head, limbs and major organs 
including heart, lung, liver and kidney were removed from embryo. The trunk 
was washed with PBS to remove the remaining blood. 
3. Trunk was transferred to 10mL tubes and cut into small pieces with forceps. 
4. 0.25% trypsin was added into tubes and incubating the cut trunk for 15 minutes 
at 37°C. 
5. 10% FBS DMEM medium was added into tube and pipet vigorously to break 
down the tissue into cells suspension. 
6. Precipitating the cell suspensions by gravity for 1 minute to let remaining clumps 
sinking to the tube bottom. 
7.  The supernatant was transfer to new tubes and spun down with 200g for 2 
minutes, the cell pellet was washed with fresh medium and spun down again. 
8.  Cells were re-suspended with 10% FBS DMEM medium and seeded into 10cm 
dish. 
9. After overnight culture, medium was changed and all suspending cells were 
removed with PBS washing. The remaining attached cells were MEF cells. 
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Figure 6.1 Strategy of generation SMP5 gene trap mutant mice in C57BL/6 strain. 
13 exons were included in SMP5 transcripts and a prepared cassette was inserted into 
intro 2. With the stop code in cassette, transcription of SMP5 will be stopped 
immediately after exon 1 and IRES in cassette can help to transcript the β-geo gene 
which is fused to the incomplete SMP5 transcripts.(Red arrows present the primers for 
genotyping)  
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GENOTYPING 
2~3 mm mouse tail was cut for genome DNA extraction. The tail was lysed with 
100 μl 50mM NaOH at 100°C for 30 minutes. The lysate was neutralized with 9 μl 1M 
Tris.HCL pH6.5. 1.5 μl neutralized lysate was used as the DNA template for genotyping 
with genotype primers (Table 2.1). 
WESTERN BLOTTING 
MEF cells were cultured in 6 wells plate to reach 70% confluence. Harvest the 
cells with 2XSDS western loading buffer and boil the lysate for 10 minutes. Sample was 
subjected to western blotting to verify the SMP5 protein level. 
RESULTS AND DISCUSSION 
To study the role of SMP5 in mouse, gene trap strategy was used to generate the 
whole body SMP5 knockout mouse. SMP5 knockout mouse was gotten successfully and 
MEF cells were isolated to validate the knockout efficiency. First of all, the genotyping 
primers were test and the PCR product bands were separated and detect by 2.0% 
Agarose gel electrophoresis. In figure 6.2, wild type, heterozygous and homozygous 
were represented by different band patterns. The wild type mouse only has one band 
with small size, the homozygous has one band with large size and the heterozygous has 
both small size band for wild type allele and big size band for knockout allele. 
Secondary, qPCR was applied to verify the SMP5 mRNA level in MEF cells. The 
primers were designed to target sequence after exon 2 which should be deleted in 
homozygous due to the transcription terminator on LacZ cassette insertion in intron 2. 
We found there is only trace amount of SMP5 mRNA can be detected in homozygous 
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comparing to wild type littermate control. Finally, we checked the protein level of SMP5 
in MEF cells, the western data showed that the SMP5 protein level is dramatically 
decreased in homozygous comparing to control but there is still detectable SMP5 protein 
in homozygous MEF cells. Based on the qPCR and western blotting data, we confirmed 
that the SMP5 level is significantly decreased in homozygous. The remaining trace 
amount of SMP5 protein which is found in homozygous MEF cells may due to the 
expression leaky of SMP5. Considering the dramatically decrease in SMP5 protein level 
in homozygous, the mouse line is suitable for further studying the physiological role of 
SMP5 in animal.  
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Figure 6.2 Generation of SMP5 knockout mice. SMP5 knockout mouse was generated 
with LacZ insertion. (A) Targeting vector was inserted into SMP5 intron 2 and the 
insertion was verified by PCR. (B) Deletion of SMP5 gene was verified by qPCR (C) 
and western blotting (D) in MEF cells. 
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CHAPTER VII  
SMP5 KNOCKOUT MOUSE HAS NEONATAL LETHAL 
PHENOTYPE WITH DEFECTED GLUCONEOGENESIS 
INTRODUCTION 
SMP5 knockout mouse was generated to explore the SMP5 function in animal. 
The SMP5 expression pattern was profiled by using In Situ hybridization. Since SMP5 
was found to affect glucose production through regulate FoxO1/3a phosphorylation 
status, we explored the phenotype of the SMP5 knockout mouse, especially focus on 
glucose homeostasis of the homozygous. 
MATERIALS AND METHODS 
IN SITU  HYBRIDIZATION 
To reveal the expression pattern of SMP5 in mouse whole body, SMP5 cDNA 
was re-cloned into pBluescriptKS and pBluescriptSK as the template for In situ 
hybridization RNA probes synthesis. 20μg pBluscriptKS SMP5 and pBluscriptSK SMP5 
were digested with BamHI at 37°C. The linearized DNAs were purified with phenol-
choloroform. After concentration measuring, 3.6μg DNA templates were used to 
generate Digoxigenin labeled probes by using the Digoxigenin labeling kit (Roche 
Cat#11277073910) and T3 or T7 reverse transcriptase. The DNA templates were 
removed by DNaseI digesting and RNA probes were precipitated with 75% pre-cooled 
EtOH containing 0.4M LiCl2 at -80°C. The probe pellets were washed with 75% EtOH 
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and dissolved with DEPC water. The dissolved probes were treated with hydrolysis 
buffer (0.06M Na2CO3, 0.04M NaHCO3) at 60°C for 20 minutes to get smaller size 
probes (around 300 bps) to enhance the hybridization efficiency. After neutralized the 
reaction mixture with neutralization buffer (0.2M NaC2H3O2, 1% acetic acid) the probes 
were precipitated and re-suspended with DEPC water. Followed with concentration 
measurement, probes were aliquoted into individual tubes for further using.  
The pregnant mouse was sacrificed at 16 days after plug was observed. The 
embryos were fixed with 4%PFA and followed with standard protocol for dehydration 
and wax embedding. 5μm sagittal sections were cut for In Situ hybridization.  
For In Situ hybridization, the sections were treated with standard de-waxing and 
re-hydration protocol (all staffs are RNAase free). The PBS re-hydrated slides were 
treated with proteinase K (Proteinase K 30μg/ml, 0.05M Tris-HCl pH8.0, 50μM EDTA 
pH8.0) for 10 minutes at room temperature. The slides were post-fixed with 4%PFA for 
20 minutes at room temperature and washed twice with PBS and then washed twice with 
2X SSC buffer (150mM NaCl, 15mM trisodium citrate, pH 7.0). Then, the slides were 
pre-hybridized with hybridization buffer (50% Formamide, 5XSSC, pH4.5~5, 1% SDS, 
50μg/ml yeast tRNA, 50μg/ml heparin) without probes for 2 hours at 55°C. Sense and 
antisense SMP5 probes were diluted in hybridization buffer to final concentration 
400ng/ml. The probes were heated for 95°C for 2 minutes on heat block and chilled on 
ice immediately to dehybridize the RNA probes. 50μl hybridization solution was applied 
to the section at 50°C overnight with humidity chamber. After probes hybridization, 
slides were washed with SSC washing buffer (2 X SSC, 50% formamide) for 2 X 30 
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minutes at 55°C. Then, slides were washed with 1X MABT (100 mM maleic acid, 
150mM NaCl, 0.1% Tween20, pH 7.5) for 2 X 30 minutes at room temperature. The 
washed sections were blocked with blocking buffer (2% block reagent: Roche cat# 
11096176001 in 1X MABT with 20% heat inactivated sheep serum) for 2 hours at room 
temperature and followed with 1:250 dilution of anti-DIG alkaline phosphatase antibody 
(Roche cat# 11093274910) in a humidified chamber at 4°C overnight. The slides were 
washed with 2μM levamisole contained MABT for 5 X 30 minutes at room temperature 
and followed with NTMT( 100mM NaCl, 100mM Tris-HCl pH9.5, 50mM MgCl2, 1% 
Tween 20) washing for 2 X 5 minutes at room temperature. After washing, the sections 
were incubated with BM purple substrate (Roche Cat#11442074001) in dark humidity 
chamber for signal development. The sections were washed with PBS and post-fixed 
with 4%PFA for 20 minutes to stabilized staining. Finally, the slides were washed with 
PBS and mounted with aqueous mounting solution. 
BLOOD GLUCOSE MEASURMENT 
Blood was collected from natural delivered P0 pups or E18.5 embryos from C-
section. Blood glucose concentration was measured with Contour® Blood Glucose 
Meter. 
GLUCOSE AND PYRUVATE INJECTION RESCUE 
E18.5 embryos were dissected out with C-section and injected with 20μl glucose 
(10% glucose and 0.9% sodium chloride in dd H2O) or 20μl pyruvate (10% pyruvate and 
0.9% sodium chloride in dd H2O) every 6~8 hours. Mouse status was checked every one 
hour. 
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RNA AND PROTEIN EXTRACTION 
Liver and pancreas were dissected out from sacrificed mouse. After rising with 
PBS, liver was separated to two parts for RNA and protein respectively. For protein 
sample, the liver was homogenized in cold RIPA buffer with protease inhibitor and 
centrifuged with 12,000 rpm for 10 minutes at 4°C. The supernatant was kept and the 
concentration was measured with Bio-Rad protein assay kit (Cat#500-0001). For RNA 
sample, the liver and pancreas were homogenized in 1ml cold Trizol solution and kept at 
room temperature for 5 minutes to complete dissociate nucleoprotein complexes. 200μl 
chloroform was added into tube and mixed well with shaking tube vigorously by hand 
for 15 seconds. The mixture was incubated at room temperature for 2 to 3 minutes. Then 
the sample was centrifuged with 12,000g for 15 minutes at 4°C. Supernatant was 
collected and 0.5ml isopropyl alcohol was added to precipitate total RNA. After spin 
down, the pellet was washed with 70% EtOH and re-suspended with DEPC water. The 
RNA concentration was measured with spectrometry. 
QPCR 
1μg RNA was used for template and multiple genes were checked by using 
primers in the list. (Table 2.1) 18S was used as the internal control. 
WESTERN BLOTTING 
Protein samples were subject to different concentration SDS PAGE for different 
sizes protein molecules. 13.5% SDS PAGE was used for LC-3, 10% SDS PAGE was 
used for other proteins.  
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LIVER FRACTIONATION 
After 12 hours fasting, mouse was sacrificed and liver was dissected out. Liver 
was transferred into 1ml VWR® Dounce homogenizer pre-chilled on ice with 1ml A 
buffer containing protease cocktail (aprotinin, leupeptin, and phenylmethylsulfonyl 
fluoride) and phosphatase inhibitors (NaF, Na3VO4). Grinding the liver gently with 4 
times push. Lysate was spin down with 1,200g for 10 minutes at 4°C. The pellet was 
washed with 1ml A buffer and spin down with 1,200g for 5 minutes at 4°C. Pellet was 
lysed with 200μl buffer B containing protease cocktail (aprotinin, leupeptin, and 
phenylmethylsulfonyl fluoride) and phosphatase inhibitors (NaF, Na3VO4) for the 
nucleus fractionation. 
IMMUNOHISTONCHEMISTRY 
Liver sample was fixed with 4%PFA. The fixed sample was dehydrated and 
embedded with standard protocol. 5μm section was cut for immunohistochemistry.  
PSA STAINING  
5μm sections were treated with standard de-waxing and re-hydration process. 
After re-hydration, sections were oxidized with 0.5% periodic acid solution (Sigma 
Cat#7875) for 5 minutes and rinsed in distilled water. Schiff reagent (Sigma 
Cat#3952016) was applied to sections for 20 minutes and removed with tap water 
washing for 5 minutes. Slides were counterstained with hematoxylin for 1 minute and 
washed with tap water for 5 minutes. Finally, slides were dehydrated and mounted with 
synthetic mounting medium. 
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RESULTS AND DISCUSSION 
To profile the expression pattern of SMP5, In situ hybridization approach was 
used by using probe synthesized from SMP5 cDNA template. As shown in Figure 7.1, 
positive signal can be detected by using anti-sense probe but cannot be detected with 
sense probe which suggests the bind between probe and target mRNA is specifically. 
Based on the signal distribution pattern, we found that SMP5 is expressed in most of the 
major organs and tissues including brain, heart, lung, liver, kidney and intestine. To 
further investigate SMP5 function in vivo, the SMP5 knockout mouse was generated 
from a gene trap C57BL/6 ES cell line. Interestingly, the SMP5 knockout mouse dies 
within 24 hours after birth. Due to the neonatal lethal phenomenal, mice heterozygous 
for the SMP5 deletion were used to keep the line. The day 1 progeny of heterozygous 
breeding was analyzed by PCR (Figure 6.2B). At day 1, besides the slightly small body 
size of the homozygous the progenies were phenotypically similar to their heterozygous 
and wild type littermates and the progenies displayed the expected Mendelian ratio of 
mice heterozygous and homozygous for the SMP5 deletion. The Mendelian ratio at P0 
suggests the SMP5 knockout can survive until deliver. Mouse neonatal lethality can be 
caused by numerous defects. Lung, cardiovascular, neuromuscular and skeletal defects 
can cause respiration problems and the neonate has these defects will undergo 
asphyxiation and die soon after birth. Craniofacial defects and parental behavior also 
play important roles in mouse neonatal lethal phenomenal by which the neonate cannot 
get the milk supply successfully. Finally, both the skin defect and renal failure can cause 
body fluid homeostasis problem and glucose homeostasis related hypoglycemia can  
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Figure 7.1 SMP5 expresses in major organs of wild type mouse.  E16.5 C57BL/6 wild 
type mouse embryo sagittal section was hybridized with antisense (A) and sense (B) 
SMP5 probes. (C).Dot blotting for antisense and sense probes concentration verification.  
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cause the neonatal lethality due to the physiological homeostasis defaults (Turgeon and 
Meloche 2009). Since we found that SMP5 can affect glucose product in cells through 
regulating FoxO1/3a, we mainly focused on checking the blood glucose of the neonates. 
The blood glucose measurement showed that immediately after birth the readouts are 
comparable between wild type and homozygous. It is reasonable since the blood glucose 
is mainly maintained by mother before deliver and the neonates can keep the blood 
glucose level at a stable level for a while with the maternal derived glucose. The trans-
placental nutrient and energy supply are immediately terminated at birth, neonates have 
to deal with the cessation of nutrient until supply can be restored with milk (Kuma, 
Hatano et al. 2004). During the starvation period, glycogenolysis and gluconeogenesis 
are important to support the glucose homeostasis (Darlington 1999). After caesarean 
delivery, the pups were sacrificed and the livers were subjected to frozen section. PSA 
staining was applied to the frozen sections to check the hepatic glycogen storage of the 
new born pups. The staining result did not show obvious difference between wild type 
and SMP5 knockout mice samples (Figure 7.2).  To mimic the nutrient cessation, the 
neonates from caesarean delivery were starved for 12 hours and the blood glucose level 
was measured by using blood glucose meter. Consistent with the role of SMP5 in cell 
based glucose production, the SMP5 knockout has significantly decreased blood glucose 
comparing to the littermates control (either wild type or heterozygous) (Figure 7.3). To 
further confirm whether the lethal phenotype of SMP5 knockout is due to the decreased 
blood glucose, glucose injection rescue was set up and the data showed that the survive 
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time is increased in SMP5 knockout pups with glucose injection comparing to the 
knockout pups with saline injection only (Figure 7.4). This result suggests exogenous 
glucose input can at least partially rescue the lethal phenotype of SMP5 knockout 
moues.  
 
 
 
 
 
 
 
 
Figure 7.2 Glycogen storage is not affected in SMP5 Knockout mouse liver. P0 
mouse liver was fixed and stained with PAS. Pink color represents the glycogen. 
 
 
 
 
 
 
 
 
WT Homo 
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Figure 7.3 SMP5 knockout mouse blood glucose is significant lower than control. 
After caesarean section, the mouse embryos were starved for 12 hours at 30°C in a 
humidity chamber. The blood samples were collected from embryo tail and measured 
with blood glucose meter. (***: P value<0.001) 
 
 
 
 
 
 
 
 
 
 
* * * 
* * * 
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Figure 7.4 Glucose injection can elongate SMP5 knockout survive time. After 
caesarean section, the mouse embryos were injected with glucose every 6~8 hours and 
observed every hour at 30°C in a humidity chamber. 
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Besides liver, SMP5 expression also presents in other major organs such as brain, 
heart and lung. The multiple organs expression suggests SMP5 not only play a role in 
liver for glucose homeostasis, it also may have other important roles in different organs. 
The partial but not fully rescue with glucose injection may due to the potential 
complexity of SMP5 functions. Pancreas secreted hormones including insulin and 
glucagon are important molecules which regulate blood glucose level. To investigate 
whether the dropping blood glucose in SMP5 knockout mouse is due to the abnormal 
insulin or glucagon secretion, pancreas insulin and glucagon mRNA level were verified 
with qPCR and no significant difference was found in homozygous mouse samples 
(Figure 7.7). Multiple genes which are related to hepatic glucose production were 
checked by using qPCR. We found the glycogenolysis and glycogenesis related genes 
are not changed in SMP5 homozygous liver, but consistent to the cell based assay 
expression of PEPCK1 and G6PC which are important for gluconeogenesis are 
significantly decreased (Figure 7.6).  The pyruvate injection cannot elongate the survive 
time of SMP5 knockout mice also support the hypothesis that the blood glucose 
decreasing is due to insufficient PEPCK1 in SMP5 knockout mouse liver  since pyruvate 
is the substrate for glucose synthesis (Figure 7.5). Autophagy in SMP5 knockout mouse 
liver was checked to further exclude the possibility of substrates for gluconeogenesis 
since autophagy is important for the fasting neonate to generate substrates for 
gluconeogenesis such as glucogenic amino acids (Kuma, Hatano et al. 2004). Western 
blotting of autophagy marker LC-3 showed that autophagy is normal in SMP5 knockout 
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mouse which suggests the substrates supply of gluconeogenesis is not affected in SMP5 
knockout mouse (Figure 7.8). 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5 Pyruvate injection cannot elongate SMP5 knockout survive time. After 
caesarean section, the mouse embryos were injected with pyruvate every 6~8 hours and 
observed every hour at 30°C in a humidity chamber. 
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Figure 7.6 PEPCK1 and G6PC expression are decreased in SMP5 knockout mouse 
liver. Glucose metabolism related genes were analyzed with quantitative PCR. Pygl, 
Gys1 and Gys2 expression level are comparable for wild type and SMP5 knockout. 
PEPCK1 and G6PC expression are decreased in SMP5 knockout mouse liver. 
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Figure 7.7 Hormones mRNAs level is not affected in SMP5 knockout mouse 
pancreas. Insulin and Glucagon mRNA level was measured by qPCR and no significant 
difference was found in SMP5 knockout mouse pancreas. 
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The expressions of major transcription activators and co-factors were also be 
tested with qPCR, the data showed that like other genes the expression level of 
FoxO1/3a does not change in SMP5 knockout mouse (Figure 7.9). Because SMP5 was 
shown to be a phosphatase of FoxO1/3a in cell based system, serine256/253 of 
FoxO1/3a respectively were checked in SMP5 knockout mice and their littermates’ 
livers. Not surprisingly, phosphorylation of serine256/253 is increased in knockout mice 
(Figure 7.10). Akt is an important FoxO1/3a kinase which can phosphorylate FoxO1/3a 
at serine265/253 respectively and regulate FoxO1/3a transcription activity (Paradis and 
Ruvkun 1998; Brunet, Bonni et al. 1999; Rena, Guo et al. 1999). Total Akt and Akt 
activated form (pS473 Akt) were also tested, western blotting showed the total Akt does 
not change and activate form is slightly decreased in SMP5 knockout liver which means 
the phosphorylation increasing of FoxO1/3a is not due to the increase of kinase activity 
(Figure 7.10). Increasing phosphorylation of FoxO1/3a can enhacne their nucleus export, 
liver FoxO3a subcellular distribution was checked with tissue fractionation and 
immunohistochemistry. Both fractionation data and immunohistochemistry resulte 
showed the nucleus localized  FoxO3a is decreased in SMP5 knockout mouse liver 
(Figure 7.11 and Figure 7.12). 
In summary, SMP5 knockout mice die within 24 hours after birth with severe 
hypoglycemia. The hypoglycemia is due to defect in gluconeogenesis related genes, 
PEPCK1 and G6PC, expression. The decreasing of PEPCK1 and G6PC is caused by 
repressiong FoxO1/3a transcription activity through decreasing FoxO1/3a 
dephosphorylation. 
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Figure 7.8 Autophagy is not affected in SMP5 knockout mouse liver. Paired 
littermates liver lysates were harvested from 12 hours fasted neonates and subjected to 
western blotting using LC-3, β-actin and GAPDH antibodies as indicated. 
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Figure 7.9 Important transcription factors and co-activators are not affected in 
SMP5 knockout mouse liver. RNA samples were isolated from neonates after 12 hours 
starvation and genes expression were measured with qPCR. 
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Figure 7.10 Phosphorylation of FoxO1/3a is increased in SMP5 knockout mouse 
liver and the increase is not due to increasing Akt activity. Livers from neonates after 
12 hours starvation were lysed and subjected to western blotting using phospho-FoxO1, 
FoxO1, phospho-FoxO3a, FoxO3a, phospho-Akt, Akt, SMP5 and GAPDH as indicated. 
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Figure 7.11 Nucleus localized FoxO3a is decreased in SMP5 knockout mouse liver. 
Fractionation liver samples from neonates after 12 hours starvation were subjected to 
western blotting using SMP5, FoxO3a, Lamin A/C, β-actin and GAPDH as indicated. 
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Figure 7.12 Nucleus localized FoxO3a is decreased in SMP5 knockout mouse liver. 
Sections from neonate liver after 12 hours starvation were stained with FoxO3a antibody 
and counter stained with hematoxylin. Red arrows indicate nucleus and cytoplasm 
localized FoxO3a. 
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CHAPTER VIII  
CONCLUSION AND FUTURE DIRECTION 
INTRODUCTION 
Gluconeogenesis is a physiological process through which the organ can de novo 
synthesize glucose through non-carbohydrate carbon substrates including pyruvate, 
lactate, glucogenic amino acids and fatty acid. It is the major compensation mechanism 
for stabilizing blood glucose level after the body is running out of glycogen storage 
during prolonged starvation. PEPCK1 and G6PC are two key rate-limiting enzymes 
which control the speed and yield of gluconeogenesis. Regarding the important roles of 
PEPCK1 and G6PC, the expressions of PEPCK1 and G6PC are tightly regulated in vivo 
in order to keep the stable blood glucose level. Multiple transcription factors and co-
factors are reported to regulate the expression of PEPCK1 and G6PC. FoxO1 and 
FoxO3a are two important factors of these transcription factors which regulate PEPCK1 
and G6PC genes expression. There are Ser/Thr sites distribute on FoxO proteins which 
can be phosphorylated by different Ser/Thr kinase. After phosphorylating by Akt/PKB, 
FoxO proteins will be exported from nucleus to cytoplasm and then the transcription 
activity of FoxO is repressed (Biggs, Meisenhelder et al. 1999; Brunet, Bonni et al. 
1999; Kops, de Ruiter et al. 1999). Controversy to the repression effect of Akt, there are 
phosphatases can antagonize the inhibition of Akt through dephosphorylating the sites 
which are phosphorylated by Akt. Phosphatases PP2A and MKP3 (DUSP6) can 
dephosphorylate FoxO1 and facilitate its nucleus sustaining (Yan, Lavin et al. 2008; Wu, 
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Jiao et al. 2010). MKP3 was reported to be a cytosolic phosphatase for FoxO1 and PP2A 
was shown to be a phosphatase of FoxO1 with role in cell apoptosis (Xu, Yang et al. 
2005; Yan, Lavin et al. 2008). Since the FoxO1/3a kinas Akt can be activated in nucleus 
(Wang and Brattain 2006; Villarejo-Balcells, Guichard et al. 2011), in principle, it is 
possible that there is nucleus located phosphatase exist which regulate FoxO1/3a in 
glucose homeostasis. 
SUMMARY 
In this study, we identified SMP5 (a member of the small C-terminal domain 
phosphatase) as a novel FoxO1/3a phosphatase. Interestingly, SMP5 protein level is 
regulated during fasting/feeding cycle in wild type mouse which suggests its role in 
metabolism homeostasis (Figure 2.1). Overexpression of SMP5 leads to reduction of the 
endogenous phospho-FoxO1/3a and this effect depends on the phosphatase activity 
(Figure 2.4). Knocking down SMP5 can increase the endogenous phospho-FoxO1/3a 
(Figure 2.5). Furthermore, purified recombinant SMP5 can directly dephosphorylate 
phospho-FoxO1/3a in vitro (Figure 2.6). These results suggest that SMP5 is a 
phosphatase for dephosphorylation of FoxO1/3a in the PI3K-Akt axis.  
  DISCUSSION 
Unlike MKP3 which is also a FoxO1 phosphatase located in cytoplasm (Wu, Jiao 
et al. 2010), SMP5 is a nucleus localized protein (Figure 2.2 and 2.3). Overexpressing 
SMP5 can enhance FoxO1/3a nucleus sustaining through dephosphorylating FoxO1/3a 
and in turn disrupting interaction between FoxO1/3 and 14-3-3ζ (Figure 4.4). Given the 
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role of FoxO1/3a in PEPCK1 and G6PC transcription regulation, the glucose production 
is repressed in SMP5 knock down HepG2 cells (Figure 5.4). Consistent with the role of 
SMP5 in cell, phospho-FoxO1/3a is significantly increased and in SMP5 knockout 
mouse liver and the gluconeogenesis related genes expression is decreased as a 
consequence (Figure 7.6 and 7.10). The animal based experiment data indicates the role 
of SMP5 in hepatic glucose production through regulating FoxO1/3a activity. 
Gluconeogenesis is important for blood glucose homeostasis especially for the animal or 
human undergoing prolonged starvation. Besides the role of SMP5 in perinatal 
starvation related glucose homeostasis, it is worthwhile to further investigate the 
function of SMP5 in adult mouse or human glucose metabolism. The creation of SMP5 
conditional knockout mouse is a suitable approach to study its role in glucose 
homeostasis in adult mouse since the whole body SMP5 knockout homozygous has 
neonatal lethal phenotype. 
FUTURE DIRECTION 
Interestingly, the SMP5 knockout mouse died within 24 hours after birth and 
glucose injection can only extend the survive time for about 20 hours more. The partially 
rescue with glucose injection suggests glucose metabolism defect may not be the only 
problem in SMP5 knockout mouse. Regarding the broad expression pattern of SMP5, it 
is possible that SMP5 has other roles in different organs since as the substrates of SMP5, 
FoxO1/3a, also express in multiple tissues and organs (Hosaka, Biggs et al. 2004). 
Additionally, besides FoxO proteins SMP5 may have other substrates as a phosphatase, 
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since based on the kinases to phosphatases ratio a protein phosphatase must have 60 to 
70 substrates in vivo as average.  
SMP5 knockout mouse was further characterized at different stage of embryo 
development. Besides liver, the other major tissues and organs were checked including 
brain, heart, lung and kidney. Ventricle septum defect (VSD) was found in SMP5 
knockout mice heart and the penetration is around 70% (Figure 8.1 and Figure 8.2). The 
involvement of FoxO proteins in cardiovascular development has been found by 
different laboratories. FoxO1 knockout mouse dies before birth by day E10.5 to E11 
with grossly vascular and cardiac development defects (Furuyama, Kitayama et al. 
2004). Interestingly, the cardiac specific ectopic expressing FoxO1 can cause the 
embryonic lethal at E10.5 with heart failure which due to the impaired cardiomyocyte 
proliferation and reduced myocardium thickness (Evans-Anderson, Alfieri et al. 2008). 
The knockout and overexpression FoxO1 induced embryonic heart development defects 
suggest the sophistically regulation of FoxO1 activity is required for the heart 
development. FoxO3a involves the endothelial cells migration and sprouting during 
development through repression BMPER (BMP-binding endothelial cell precursor 
derived regulator) expression (Moser, Binder et al. 2003; Heinke, Wehofsits et al. 2008). 
Given the role of SMP5 as a phosphatase of FoxO1/3a, the function of SMP5 in 
cardiovascular development is need to be further studied. 
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Figure 8.1VSD is found in  SMP5 knockout mouse heart I. C-section delivered mice 
were perfused with PBS and fixed with PFA through Venae umbilicalis. Wax embedded 
hearts were subjected to cross section and HE staining. (RA: right atrium, LA: left 
atrium, TV: tricuspid valve, MV: mitral valve, RV: right ventricle, LV: left ventricle, 
VSD: ventricle septum defect) 
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Figure 8.2 VSD is found in SMP5 knockout mouse heart II. Amplification of Figure 
8.1., VSD  was  marked with yellow arrow (TV: tricuspid valve, MV: mitral valve, RV: 
right ventricle, LV: left ventricle) 
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Besides the function on metabolism, FoxO proteins are also involved in 
regulating cells proliferation and apoptosis. Due to their function on regulating the cell 
cycle, apoptosis and DNA repair, FoxO proteins have long been considered to be the 
tumor suppressors (Brunet, Bonni et al. 1999; Medema, Kops et al. 2000; Kops, Dansen 
et al. 2002; Kops, Medema et al. 2002; Tang, Dowbenko et al. 2002; Tran, Brunet et al. 
2002; Seoane, Le et al. 2004). The potential role of SMP5 in tumorigenesis through 
regulating FoxO proteins phosphorylation status is also a worthful investigation 
direction.  
The expression of SMP5 is changing in mouse liver under different metabolism 
profile (Keller, Choi et al. 2008) which is further confirmed in my dissertation study by 
using western blotting (Figure 2.1). The varied protein level of SMP5 during fasting-
feeding cycle suggests endogenous SMP5 is regulated and this regulation is highly 
related to metabolism homeostasis. Elucidating the mechanism through which SMP5 is 
regulated may enhance our understanding on blood glucose homeostasis and find new 
therapy target for diabetes. 
In summary, we identified SMP5 as a FoxO1/3a phosphatase. SMP5 can interact 
and dephosphorylate FoxO1/3a in vitro and in vivo. Manipulating SMP5 expression in 
cells can mediate FoxO1/3a transcription activity through affect their subcellular 
localization (Figure 8.3). SMP5 knockout mouse has increasing phospho-FoxO1/3a in 
liver and decreasing gluconeogenesis related genes, PEPCK1 and G6PC, expression 
which associate with hypoglycemia. The finding of the gluconeogenesis related new 
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phosphatase may facilitate new therapeutic strategies developing for diabetes and 
glucose metabolism related disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.3 The working model of SMP5 regulating FoxO1/3a transcription activity. 
SMP5 facilitates FoxO1/3a nucleus sustaining through dephosphorylating FoxO1/3a and 
attenuating insulin signaling. 
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